Aducanumab-avwa

From WikiMD.org
Jump to navigation Jump to search

Aducanumab-avwa

Aducanumab-avwa (pronounced as ad-yoo-KAN-yoo-mab-av-wa) is a monoclonal antibody medication used for the treatment of Alzheimer's disease.

Etymology

The name "Aducanumab-avwa" is derived from the generic name "Aducanumab", which is a type of monoclonal antibody specifically designed to target and remove beta-amyloid plaques in the brain, which are a common hallmark of Alzheimer's disease. The suffix "-avwa" is a regulatory designation indicating the specific formulation and manufacturing process of the drug.

Usage

Aducanumab-avwa is used in the treatment of Alzheimer's disease. It is administered via intravenous infusion. The drug works by binding to beta-amyloid plaques in the brain and promoting their removal, which can help to slow the progression of Alzheimer's disease.

Related Terms

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
  • Beta-amyloid plaques: Clumps of beta-amyloid protein that accumulate in the brains of people with Alzheimer's disease.
  • Alzheimer's disease: A progressive brain disorder that affects memory, thinking skills, and the ability to carry out simple tasks.
  • Intravenous infusion: A method of delivering medication or other substances directly into a vein.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski